Home / Clinical trials / Dulaglutide
Are there clinical trials for Dulaglutide?
Dulaglutide has 142 registered clinical trials, including 88 completed interventional studies and trials reaching Phase 4. Its use in humans is supported by established registered clinical evidence.
Trial breakdown
By phase
| Phase 3 | 36 |
| Phase 2 | 28 |
| Phase 4 | 25 |
| Phase 1 | 24 |
| Not applicable | 8 |
By status
| Completed | 102 |
| Unknown status | 13 |
| Recruiting | 9 |
| Not yet recruiting | 7 |
| Active, not recruiting | 5 |
| Enrolling by invitation | 3 |
| Terminated | 3 |
Active trials
- GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF RegistryNot yet recruiting · 150 participants · Miedziowe Centrum Zdrowia SA · started 2027-01-01NCT07787936
- Metabolic Surgery for Atrial Fibrillation EliminationPhase 4 · Not yet recruiting · 100 participants · Ali Aminian · started 2026-11-01NCT07027969
- Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes MellitusPhase 2 · Not yet recruiting · 60 participants · ProGen. Co., Ltd. · started 2026-10NCT07677891
- A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesPhase 3 · Not yet recruiting · 170 participants · Eli Lilly and Company · started 2026-09NCT07668336
- Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor AgonistsRecruiting · 300 participants · Ohio State University · started 2026-06-12NCT07702461
- Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney DiseasePhase 4 · Not yet recruiting · 468 participants · First Affiliated Hospital of Wannan Medical College · started 2026-05NCT07537088
- Role of GLP1 RA Dulaglutide on Severe Intracranial AtherosclerosisPhase 2 / Phase 3 · Recruiting · 130 participants · National University of Singapore · started 2025-12-17NCT07282041
- Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric RetentionNot yet recruiting · 16509 participants · Fudan University · started 2025-12-10NCT07276763
Most recent registered trials
- GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF RegistryNot yet recruiting · 150 participants · Miedziowe Centrum Zdrowia SA · started 2027-01-01NCT07787936
- Metabolic Surgery for Atrial Fibrillation EliminationPhase 4 · Not yet recruiting · 100 participants · Ali Aminian · started 2026-11-01NCT07027969
- Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes MellitusPhase 2 · Not yet recruiting · 60 participants · ProGen. Co., Ltd. · started 2026-10NCT07677891
- A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesPhase 3 · Not yet recruiting · 170 participants · Eli Lilly and Company · started 2026-09NCT07668336
- Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor AgonistsRecruiting · 300 participants · Ohio State University · started 2026-06-12NCT07702461
- Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney DiseasePhase 4 · Not yet recruiting · 468 participants · First Affiliated Hospital of Wannan Medical College · started 2026-05NCT07537088
- Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.Completed · 300000 participants · Brigham and Women's Hospital · started 2026-02-03NCT07417631
- INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)Completed · 60000 participants · Brigham and Women's Hospital · started 2026-01-27NCT07417618
- Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular RiskCompleted · 120000 participants · Brigham and Women's Hospital · started 2026-01-20NCT07619495
- A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes MellitusPhase 1 · Completed · 20 participants · Eli Lilly and Company · started 2025-12-29NCT07313813
- Role of GLP1 RA Dulaglutide on Severe Intracranial AtherosclerosisPhase 2 / Phase 3 · Recruiting · 130 participants · National University of Singapore · started 2025-12-17NCT07282041
- Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric RetentionNot yet recruiting · 16509 participants · Fudan University · started 2025-12-10NCT07276763
Frequently asked questions
Are there clinical trials for Dulaglutide?
Dulaglutide has 142 registered clinical trials, including 88 completed interventional studies and trials reaching Phase 4. Its use in humans is supported by established registered clinical evidence.
Does a registered trial mean the peptide works?
No. Registration means a study was formally listed before or during the research. It says nothing about the result. A completed trial can find no benefit, and many registered studies are never published.
What is the difference between a registered trial and published evidence?
Registration records that a study exists. Publication reports what it found. This page counts registrations, which is the more complete picture of research activity, but it is not a measure of proven effectiveness.
Why do phases matter?
Phase 1 tests safety in a small group. Phase 2 looks for early signs of effect. Phase 3 tests effectiveness against a comparator in a large group, and is what regulators normally require. Phase 4 studies happen after approval. A compound with only Phase 1 trials has not been shown to work.
Source: ClinicalTrials.gov API v2, U.S. National Library of Medicine. Studies where Dulaglutide is registered as an intervention. Last updated 2026-09-23.